854
Views
6
CrossRef citations to date
0
Altmetric
Original Articles

Heparin-appended polycaprolactone core/corona nanoparticles for site specific delivery of 5-fluorouracil

, , , &
Pages 1146-1155 | Received 06 Apr 2016, Accepted 16 Jun 2016, Published online: 04 Jul 2016
 

Abstract

The aim of the present work is to formulate heparin-modified-polycaprolactone (HEP) core shell nanoparticles (NPs) of 5-fluorouracil (5-FU). These NPs were characterized for various in vitro parameters like particle size, zeta potential, etc. HEP NPs were found to maintain comparatively slower drug release pattern (98.9% in 96 h) than PCL NPs. Cytotoxicity studies demonstrated a massive cytotoxic potential of 5-FU-loaded HEP NPs in A549, MDA-MD-435, and SK-OV-3 cancer cell lines. Pharmacokinetic parameters were also determined in blood after IV administration of HEP NPs: AUC, Cmax, MRT, and Tmax values are 6096.075 ± 5.90 μg h/mL, 144.38 ± 1.52 μg/L, 58.71 ± 0.25 h, 96 ± 0.50 h, respectively and 117.92 ± 1.78, 45.35 ± 3.00, 1.2 ± 0.25, 0.5 ± 0.02 in plain 5-FU solution.

Acknowledgements

The author acknowledges SAIF-CDRI (Lucknow, India) for NMR facility and Indian Institute of Technology (Indore, India) for providing AFM facility. The author expresses his sincere thanks to Indian Institute of Technology (Ropar, India) for providing XRD facility. The author also expresses his sincere thanks to SAIF-RGPV (Bhopal, India) for providing particle size and zeta potential facilities, and also expresses his sincere thanks to ACTREC (Mumbai, India) for providing in vitro cytotoxicity assay facility.

Disclosure statement

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of this article.

Funding information

The present research work was financially supported by MPCST, Bhopal (MP), India (Grant Number: 1766/CST/R&D/Bio, Proj/2013).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.